Promising research results for treatment of aggressive PC

@surftohealth88
I am not sure about your questions.

I am a Mayo patient and get medical information pamphlets every month. I did read about a new trial studying using some type of protein that attacks on prostate cancer cells and not normal ones.

I wish I had remembered the exact article on it but found it really helpful if works for the millions of us that get prostace cancer. You can get on Mayo and read their information on it.

I am part of the Mayo Legacy Program so I get these information letters free. I am not sure if you have to pay to join or it is free to get these informational post and the printed forms.

Maybe a monitor could comment.

Thanks for sharing that — targeting ISR looks like an interesting possibility for treating some cancers that have developed therapy resistance (like castrate-resistance for prostate cancer). It's still early days research-wise, but 🤞

Here's a research review from 2023:
https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1206561/full

Interesting article - thanks. The mutations, the mutations - this area is under development and can’t go fast enough for many of test.

If there is really something to this, why, when it was published in 2018, there weren’t treatments created by 2025.

There are no trial as of now of ISRIB or related drugs.

The article said
The researchers hope that this discovery will quickly lead to clinical trials for ISRIB or related drugs for patients with advanced, aggressive prostate cancer. “Most molecules that kill cancer also kill normal cells,” Ruggero said. “But with ISRIB we’ve discovered a beautiful therapeutic window: normal cells are unaffected because they aren’t using this aspect of the UPR to control their protein synthesis but aggressive cancer cells are toast without it.”

Something must not have worked as hoped.

That's the problem with overhyped, misleading headlines like "Research Finds ‘Achilles Heel’ for Aggressive Prostate Cancer." There are a few reasons we're not there yet:

- that was very early-stage research in 2018
- ISRRIM may have serious or even catastrophic long-term side-effects that we don't fully understand yet, so they're going cautiously before human trials
- most of the research interest and investment in ISRIB is centred around treating Alsheimer's https://en.wikipedia.org/wiki/ISRIB
- the early research cited in the article is specific to castrate-resistant prostate cancer that involves the MYC genetic mutation and PTEN-suppression mutation in combination